Akebia Therapeutics to Present at the 2026 Jefferies Global Healthcare Conference
Rhea-AI Summary
Akebia Therapeutics (Nasdaq: AKBA) announced that Chief Financial and Business Officer Erik Ostrowski and Chief Commercial Officer Nicholas Grund will present at the 2026 Jefferies Global Healthcare Conference on June 4, 2026, at 7:35 AM ET in New York.
A live and 90-day replay webcast will be available via Akebia's investor website.
Positive
- None.
Negative
- None.
News Market Reaction – AKBA
In the May 28 session, AKBA gained 1.94%, reflecting a mild positive market reaction.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Historical Context
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| May 07 | Q1 2026 earnings | Negative | -20.3% | Reported Q1 net loss and revenue decline versus prior year, highlighting pressure. |
| May 04 | Inducement grants | Neutral | -3.3% | Announced stock option inducement grants to new employees under Nasdaq rules. |
| May 04 | Clinical analysis | Positive | +7.1% | Post‑hoc win statistics analysis showed significant mortality and hospitalization benefit. |
| Apr 30 | Earnings date notice | Neutral | +1.4% | Set date and webcast details for upcoming Q1 2026 earnings call. |
| Apr 13 | Phase 1 initiation | Positive | +5.0% | First participants dosed in Phase 1 trial of AKB‑9090 for AKI. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Recent news, including earnings and clinical updates, has generally seen price moves that align with the tone of the announcement, with notably sharp downside after weaker financials.
Over the last few months, Akebia has mixed financial pressure with clinical progress. Q1 2026 results on May 7 showed a net loss and revenue decline, and the stock fell 20.27%. Earlier in April, initiation of a Phase 1 trial for AKB‑9090 and positive vadadustat analysis both saw positive reactions of 5% and 7.14%. Against this backdrop, a Jefferies conference appearance fits into ongoing investor outreach rather than a new clinical or financial catalyst.
AI-generated analysis. How Rhea-AI works. Not financial advice.
CAMBRIDGE, Mass., May 28, 2026 (GLOBE NEWSWIRE) -- Akebia Therapeutics®, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today announced that Erik Ostrowski, Chief Financial and Business Officer, and Nicholas Grund, Chief Commercial Officer, will present at the 2026 Jefferies Global Healthcare Conference on Thursday, June 4, 2026 at 7:35 AM ET in New York, NY.
A live webcast of the presentation can be accessed through the “Investors” section of Akebia’s website at https://ir.akebia.com. A replay of the webcast will also be available for 90 days following the presentation.
The 2026 Jefferies Global Healthcare Conference will take place June 2-4, 2026, in New York, NY.
About Akebia Therapeutics
Akebia Therapeutics, Inc. is a fully integrated biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease. Akebia was founded in 2007 and is headquartered in Cambridge, Massachusetts. For more information, please visit our website at www.akebia.com, which does not form a part of this release.
Akebia Therapeutics Contact
Mercedes Carrasco
mcarrasco@akebia.com
